Core Viewpoint - Agilent Technologies is expected to report quarterly earnings of $1.37 per share, a 3.8% increase year-over-year, with revenues projected at $1.66 billion, reflecting a 5.1% year-over-year increase [1]. Financial Projections - Analysts have not revised the consensus EPS estimate for the quarter in the last 30 days, indicating stability in forecasts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3]. Revenue Estimates by Segment - The estimated 'Net Revenue- Life Sciences and Diagnostics Markets Segment' is $631.29 million, showing a year-over-year decrease of 19.3% [5]. - 'Net Revenue- Agilent Crosslab Group' is expected to reach $720.15 million, indicating a significant year-over-year increase of 75.2% [5]. - 'Revenue by End Markets- Chemical and advanced materials' is projected at $376.71 million, reflecting a 5.8% increase from the prior year [6]. - 'Revenue by End Markets- Environmental and Forensics' is estimated at $170.70 million, with a year-over-year change of 1.6% [6]. - 'Revenue by End Markets- Diagnostics and Clinical' is expected to be $249.80 million, indicating a 3.2% increase from the previous year [7]. - The consensus for 'Revenue by End Markets- Academia and Government' stands at $137.61 million, reflecting a year-over-year increase of 7.5% [7]. - 'Revenue by End Markets- Pharmaceutical' is projected at $581.31 million, indicating a year-over-year increase of 7.7% [7]. - 'Revenue by End Markets- Food' is expected to reach $150.33 million, reflecting a 4.4% increase from the prior year [8]. Stock Performance - Over the past month, Agilent shares have decreased by 2.7%, while the Zacks S&P 500 composite has increased by 1.1% [8]. - Agilent holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [8].
Unveiling Agilent (A) Q3 Outlook: Wall Street Estimates for Key Metrics